Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 19.00
Low: 17.85
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SlimBiome® Approved by Health Canada

25 Oct 2021 07:00

RNS Number : 0118Q
OptiBiotix Health PLC
25 October 2021
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

SlimBiome® Approved by Health Canada

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds that modulate the microbiome to tackle metabolic syndrome, systemic low grade inflammation, obesity and diabetes, cardiovascular disease and high cholesterol, announces that SlimBiome® has received approval for use as a licensed product for weight management by Health Canada, a Canadian federal institution responsible for helping Canadians maintain and improve their health.

 

In Canada, every supplement must be approved and authorised by Health Canada, as a licensed Natural Health Product (NHP) and receive a National Product Number (NPN). The NPN is displayed on the product label and is confirmation that a product has been assessed and found to be safe and effective with approved health claims. As part of the approval process Health Canada have validated the scientific and clinical data on SlimBiome® and determined the following health and nutrition claims can be made: -

 

· Helps to lower cholesterol levels by reducing cholesterol absorption from the gastrointestinal tract

· Helps to maintain normal blood glucose levels and supports a healthy glucose metabolism

· Helps to prevent chromium deficiency and maintains the body's ability to metabolize nutrients

· Complementary to a healthy lifestyle with a calorie-reduced diet and regular physical activity for individuals involved in weight management

· Helps to support a feeling of fullness

· Is a source of fiber and prebiotics

 

Health Canada is seen as one of the world's leading authorities on regulating functional ingredients and supplements ensuring products are safe and marketed with approved health and nutrition claims. Health Canada approval is internationally recognised as a mark of a product quality, safety, and effectiveness and can lead to shortened product registration procedures in other international markets.

 

SlimBiome® is a patented weight management ingredient supported by independent human clinical studies (Keleszade et al, 2020) which show it reduces hunger, cravings for sweet and savoury foods, and fat intake. In addition to clinical studies, independent consumer surveys have shown that customers who used SlimBiome® in combination with a calorie restricted diet lose on average 2-3lbs (1-1.5kg) per week, experience a relief from feeling hungry and have fewer cravings for food, leading to easier and more sustainable dieting.

 

SlimBiome® has achieved three major industry awards: European Weight Management Ingredient of the Year (NutraIngredients 2018), Asia Weight Management Ingredient of the Year (NutraIngredients 2019), and most recently, best weight management product in the USA (Nutrition Industry Executive Award 2021).

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are pleased to achieve product approval for SlimBiome® by one of the toughest regulatory bodies in the world. This is a significant achievement and brings further international recognition to SlimBiome® as a scientifically backed and proven weight management ingredient. It underlines the value of the investment we made in a number of human clinical studies showing SlimBiome's® effectiveness and the creation of a large IP portfolio. SlimBiome® has won three major industry awards across all regions, obtained CE marked medical device registration in Europe, and now is a weight management product with approved health and nutrition claims by Health Canada. This opens up the Canadian and North American market for new sales opportunities and provides further validation of our product in international markets."

 

Carla Fabian, Sales Director of Agropur (Optibiotix's partner in North America) commented: "Health Canada approval and recognition with an NPN number is exciting news as this allows Agropur to safely manufacture, distribute, and sell SlimBiome in the Canadian marketplace. The registration is recognised by consumers, brand owners, retailers, and professional health care workers like pharmacists and dietitians. Everyone can be assured that SlimBiome® is safe, of high quality, and can amongst others help deliver benefits with respect to cholesterol reduction, maintaining blood glucose levels and compliment a healthy lifestyle. We, along with Optibiotix, look forward to partnering with brand owners who are looking to add proven science-based weight management functionality to existing products or to assist with new product development utilising our extensive innovation resources."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAFLFIRITLFFIL
Date   Source Headline
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.